论文部分内容阅读
重组粒-巨噬细胞集落刺激因子(GM-CSF)是一种造血生长因子,已有几组报道证实 GM-CSF)可提高再生障碍性贫血患者的白细胞,但其用量多在100～500μg/M~2/d(2.5～12.5μg/kg/d)。作者报道用极小剂量 GM-CSF、部份病人合并用红细胞生成素治疗再生障碍性贫血的情况。病人和方法作者用极小剂量 GM-CSF(5～20μg/M~2/d)皮下注射治疗13例再生障碍性贫血。其中男8例、女5例,中位数年龄54(16～81)
GM-CSF, a hematopoietic growth factor, has been reported in several groups to confirm that GM-CSF can increase leukocytes in patients with aplastic anemia, but its dosage is more than 100 ~ 500μg / M ~ 2 / d (2.5 ~ 12.5μg / kg / d). The authors report the use of minimal doses of GM-CSF in combination with erythropoietin for the treatment of aplastic anemia in some patients. Patients and Methods The authors treated 13 patients with aplastic anemia by subcutaneous injection of GM-CSF (5-20 μg / M ~ 2 / d). There were 8 males and 5 females with a median age of 54 (16-81)